Becton, Dickinson and Company — Wall Street Analyst Estimates & Price Targets

BDX

NYSEHealthcareMedical - Instruments & SuppliesCIK 0000010795bd.comAbout BDX

Last close · Oct 16, 2026191.75−2.01 (−1.04%)

Market cap$52.2B

5 firms' latest targets, last 90 days: median $190.00 ($165.00–$210.00), 1% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 5 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-07	Barclays	$165.00	$204.00	▼ 19%	-8%	-14%
2026-08-13	RBC Capital	$190.00	$180.00	▲ 6%	+3%	-1%
2026-08-07	Stifel	$195.00	$169.03	▲ 15%	+11%	+2%
2026-08-06	Jefferies	$210.00	—	—	+19%	+10%
2026-07-28	UBS	$190.00	—	—	+20%	-1%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$19.4B	+3%	$4.94	-16%	est. $19.3B+0%	est. $9.61	11
2024reported	$20.2B	+4%	$5.86	+19%	est. $20.6B-2%	est. $5.96	4
2025reported	$21.8B	+8%	$5.82	-1%	est. $21.9B+0%	est. $11.30	5
2026	$19.3B	-12%	$12.67	+12%	$19.1B–$20.0B	$12.08–$12.76	6
2027	$19.7B	+2%	$13.24	+5%	$19.4B–$20.4B	$13.05–$13.80	10
2028	$20.5B	+4%	$14.16	+7%	$20.2B–$21.2B	$11.84–$16.47	10
2029	$21.1B	+3%	$15.20	+7%	$20.6B–$21.7B	$14.92–$15.77	2
2030	$21.9B	+4%	$16.28	+7%	$21.6B–$22.5B	$15.98–$16.89	1

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$190.00median target, 1% below the last close

Firms with a target · last 90 days: 5
Lowest – highest target: $165.00 – $210.00
Current grades of 13 firms: positive / neutral / negative: 7 / 6 / 0
Upgrades / downgrades · 12 months: 0 / 0
Consensus revenue growth · next 3 FY: -2% a year

Current grades

each firm's latest · 13 firms

As of	Firm	Grade
2026-08-31	Bank of America	“Neutral”
2026-08-13	RBC Capital	“Sector Perform”
2026-08-07	Piper Sandler	“Neutral”
2026-08-07	Wells Fargo	“Equal Weight”
2026-08-07	Citigroup	“Buy”
2026-08-05	TD Cowen	“Hold”
2026-07-06	Evercore ISI	“Outperform”
2026-05-11	Barclays	“Overweight”
2026-03-23	Argus Research	“Buy”
2026-02-10	J.P. Morgan	“Neutral”

3 more

2026-02-10	Jefferies	“Buy”
2026-01-07	Stifel	“Buy”
2025-12-02	Morgan Stanley	“Overweight”

Grade changes

last 24 months · 3

Date	Firm	Grade
2025-05-22	Citigroup	“Buy” → “Neutral” downgrade
2025-05-02	Piper Sandler	“Overweight” → “Neutral” downgrade
2025-05-01	William Blair	“Outperform” → “Market Perform” downgrade

45 older than 24 months

2024-10-01	Citigroup	“Neutral” → “Buy” upgrade
2023-07-24	Raymond James	“Market Perform” → “Outperform” upgrade
2023-05-05	Piper Sandler	“Neutral” → “Overweight” upgrade
2023-04-12	Keybanc	“Sector Weight” → “Overweight” upgrade
2023-01-03	Bank of America	“Neutral” → “Buy” upgrade
2022-12-12	Citigroup	“Sell” → “Neutral” upgrade
2022-07-11	Citigroup	“Neutral” → “Sell” downgrade
2022-06-24	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2021-12-08	Piper Sandler	“Overweight” → “Neutral” downgrade
2021-08-06	J.P. Morgan	“Overweight” → “Neutral” downgrade
2020-12-15	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2020-12-15	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2020-07-09	Barclays	“Equal Weight” → “Overweight” upgrade
2020-05-08	Leerink Partners	“Market Perform” → “Perform” revised
2020-02-07	TD Cowen	“Outperform” → “Market Perform” downgrade
2020-02-07	KeyBanc	“Overweight” → “Sector Weight” downgrade
2020-02-07	Raymond James	“Strong Buy” → “Outperform” downgrade
2020-02-06	CFRA	“Buy” → “Hold” downgrade
2020-01-08	Barclays	“Overweight” → “Equal Weight” downgrade
2019-05-13	Barclays	“Equal Weight” → “Overweight” upgrade
2018-06-21	J.P. Morgan	“Neutral” → “Overweight” upgrade
2018-04-10	Citigroup	“Neutral” → “Buy” upgrade
2018-03-06	BMO Capital	“Market Perform” → “Perform” revised
2017-06-30	Raymond James	“Outperform” → “Strong Buy” upgrade
2017-04-24	Evercore ISI	“In Line” → “Outperform” upgrade
2017-01-05	Raymond James	“Strong Buy” → “Outperform” downgrade
2017-01-03	J.P. Morgan	“Overweight” → “Neutral” downgrade
2016-09-23	Citigroup	“Neutral” → “Sell” downgrade
2016-02-11	Deutsche Bank	“Hold” → “Buy” upgrade
2016-01-06	Evercore ISI	“Buy” → “Hold” downgrade
2016-01-04	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2015-01-05	Raymond James	“Market Perform” → “Strong Buy” upgrade
2014-11-26	J.P. Morgan	“Neutral” → “Overweight” upgrade
2014-10-07	Stifel	“Hold” → “Buy” upgrade
2014-10-06	J.P. Morgan	“Underweight” → “Neutral” upgrade
2014-02-05	Raymond James	“Underperform” → “Market Perform” upgrade
2014-01-07	Bank of America	“Underperform” → “Neutral” upgrade
2013-09-18	Piper Sandler	“Neutral” → “Overweight” upgrade
2013-05-10	Macquarie	“Neutral” → “Outperform” upgrade
2013-01-22	Mizuho	“Buy” → “Neutral” downgrade
2013-01-03	Morgan Stanley	“Underweight” → “Equal Weight” upgrade
2012-09-24	Barclays	“Equal Weight” → “Underweight” downgrade
2012-08-03	CLSA	“Outperform” → “Underperform” downgrade
2012-08-03	Leerink Partners	“Outperform” → “Market Perform” downgrade
2012-08-01	J.P. Morgan	“Neutral” → “Underweight” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.